住院癌症合并COVID-19患者静脉血栓栓塞事件发生率的系统综述与荟萃分析
亚组分析显示实体瘤、血液肿瘤和混合类型肿瘤的VTE发生率无组间差异(P=0.67),癌症类型和发表年份对VTE发生率无显著影响。作者结论认为该人群VTE风险约9%,约为单纯癌症患者5%风险的两倍,提示需要针对性血栓预防和风险分层。
要点
- 住院癌症合并COVID-19患者合并VTE发生率为9.16%(95%CI 7.27%-11.26%)。
- 实体瘤、血液肿瘤和混合类型肿瘤亚组VTE发生率无显著差异(P=0.67)。
- 该人群VTE风险约为单纯癌症患者5%风险的两倍,需针对性血栓预防。
核心结论
- 住院癌症合并COVID-19患者VTE风险约为9%,约为单纯癌症患者5%风险的两倍。
- 研究提示需要针对性血栓预防和改善风险分层以指导临床诊疗。
研究设计与样本
- 遵循PRISMA指南的系统综述与荟萃分析。
- 检索Scopus、PubMed和Web of Science从2020年1月至2026年2月发表的文章。
- 统计分析包括固定效应和随机效应模型的合并比例、异质性评估、发表偏倚、敏感性分析和荟萃回归。
主要发现
- 合并VTE发生率为9.16%(95%CI:7.27%-11.26%),异质性显著(I2=80%,P<0.001)。
- 实体瘤亚组VTE发生率为9%(95%CI:5.5-13%,n=5)。
- 血液肿瘤亚组VTE发生率为8.2%(95%CI:5.8-10.8%,n=3)。
- 混合类型肿瘤亚组VTE发生率为9.1%(95%CI:6.4-11.9%,n=8),组间无差异(P=0.67)。
- 未发现显著发表偏倚(Egger's P=0.27;Begg's P=0.35),癌症类型(P=0.82)或发表年份(P=0.49)对VTE发生率无显著影响。
临床怎么用
- 对住院癌症合并COVID-19患者应提高VTE警惕,考虑针对性血栓预防。
- 需进一步改善该人群的风险分层以指导临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hospitalized patients with cancer and coronavirus disease 19 (COVID-19) face a high risk of venous thromboembolism (VTE) due to combined prothrombotic effects. Despite many pandemic-era reports on VTE incidence, a dedicated meta-analysis for these patients from 2020 to 2025 is missing. This study conducted a systematic review and meta-analysis to estimate pooled VTE incidence and identify potential moderators. METHODS: Following PRISMA guidelines, we searched Scopus, PubMed, and Web of Science for articles published from January 2020 to February 2026 that reported the incidence of VTE among hospitalized adult cancer patients with COVID-19. Our statistical analysis included pooled proportions, using fixed- and random-effects models, assessment of heterogeneity, publication bias, sensitivity analysis, and meta-regression. RESULTS: Fourteen studies involving 9,311 patients were included. The pooled VTE incidence was 9.16% (95% confidence interval [CI]: 7.27%-11.26%), with significant heterogeneity (I2 = 80%, P < 0.001). Subgroup analysis by cancer type showed 9% (95% CI: 5.5-13%) for solid tumors (n = 5), 8.2% (95% CI: 5.8-10.8%) for hematologic (n = 3), and 9.1% (95% CI: 6.4-11.9%) for mixed (n = 8), with no between-group differences (P = 0.67). No significant publication bias was identified (Egger's P = 0.27; Begg's P = 0.35). Subgroup and meta-regression analysis indicated no significant influence of cancer type (P = 0.82) or publication year (P = 0.49) on VTE incidence. CONCLUSION: Hospitalized cancer patients with COVID-19 face a 9% VTE risk. This is roughly double the 5% risk seen in those with cancer alone. These findings highlight the necessity for targeted thromboprophylaxis and improved risk stratification to inform clinical care.
引用
- Patsakis G, Rousas N, Sotiriadis P, et al. Incidence of Venous Thromboembolic Events in Hospitalized Cancer Patients with COVID-19: A Systematic Review and Meta-Analysis. Ann Vasc Surg. 2026. PMID: 42685896. doi:10.1016/j.avsg.2026.08.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。